BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38144305)

  • 1. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
    Mortezaee K; Majidpoor J
    Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7x in cancer immunity and immunotherapy.
    Mortezaee K
    Int Immunopharmacol; 2023 May; 118():110133. PubMed ID: 37028278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
    Charehjoo A; Majidpoor J; Mortezaee K
    Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
    Mortezaee K; Majidpoor J
    Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
    Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
    Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses.
    Mortezaee K; Majidpoor J
    Heliyon; 2023 Mar; 9(3):e14566. PubMed ID: 36950599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
    J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of B7 family checkpoint proteins in cervical cancer.
    Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
    Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
    Zhang W; Qiu Y; Xie X; Fu Y; Wang L; Cai Z
    Front Oncol; 2021; 11():647526. PubMed ID: 33869045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.